

13.05.2019

BSE Limited Department of Corporate Relationship 1st Floor, New Trade Ring, Rotunda Building Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code : 524742

National Stock Exchange of India Ltd., Department of Corporate Services Exchange Plaza, 5th Floor, C-1, Block G,Bandra Kurla Complex, Bandra (E),Mumbai – 400 051 Scrip Code : CAPLIPOINT. By BSE Listing

By NEAPS

Dear Sirs,

Sub: PRESS RELEASE - DISCLOSURE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS OF DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.

We wish to inform exchanges that, the Company has received Colombia's INVIMA approval for its small volume sterile injectable division at Puducherry.

Please find the enclosed Press Release for the above.

Thanking You,

Yours Truly, For Caplin Point Laboratories Limited

Company Secretary Enclosure: As Above

Regd. Off.: "NARBAVI", No. 3, Lakshmanan Street, T.Nagar, Chennai - 600 017. Tamil Nadu, India. Ph.: +91 44 28156653.Unit I: No. 85/3, Suthukeny Village, Mannadipet Commune, Puducherry - 605 502. Ph.: 95242 32888 / 95242 32006.Unit II: No. 19, Chinnapuliyur Village, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Thiruvallur District - 601 201. Ph.: 9445391317.Unit III: Plot No. 44, 8th Avenue, Domestic Tariff Area, Mahindra World City, Chengalpattu Taluk, Kanchipuram District-603 004.Unit IV: Survey No. 895 & 897, Guruvarajakandigai, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Thiruvallur District - 601 201. Ph.: 9788459333 / 69333.Unit V: Ashvich Tower, 2nd Floor, No. 3, Developed Plots Industrial Estate, Perungudi, Chennai – 600 096. Ph.: +91 44 24968000.



PRESS RELEASE

CAPLIN POINT GETS COLOMBIA APPROVAL FOR STERILE INJECTABLES

Chennai, May 13, 2019: **Caplin Point Laboratories Limited** (BSE: CAPLL (524742), NSE: CAPLIPOINT) has received Colombia's INVIMA approval for its small volume sterile injectable division at Puducherry. The site inspection of Unit-1 was completed on May 10th and found compliant as per INVIMA's norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP). The facility is capable of manufacturing Liquid Injectables in Vials, Ampoules, Lyophilized Vials and Pre-Filled Syringes, amongst other dosage forms.

Commenting on the approval, Mr.C.C.Paarthipan, Chairman, Caplin Point Laboratories Limited said "Colombia is part of our expansion plans into the larger markets of Latin America. It also happens to be our first approval from Unit-1 site at Puducherry. We'll be focusing on niche opportunities in Injectables in these newer geographies."

Unit-1 site currently caters to Emerging Markets of Latin America and Africa with a variety of dosage forms such as Tablets, Capsules, Softgel Capsules, Suppositories, Liquid Orals and Topicals.

ABOUT CAPLIN POINT LABORATORIES LIMITED:

Caplin Point Laboratories Limited is a fast growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point Laboratories Limited has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has also entered regulated markets such as US through its Wholly Owned Subsidiary Caplin Steriles Limited,

Caplin Point has been selected on Forbes Asia's "200 Best Under a Billion" list for three consecutive years (2014, 2015 & 2016), and was recently awarded "The Emerging Company of 2018" by Economic Times Family Business Awards.





CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations Team at Caplin Mr.Vinod Kumar (Company Secretary) Tel: +91 44 24968000 investor@caplinpoint.net

Dikshita Jain Christensen Investor Relations Tel : +91 22 4215 0210 djain@christensenir.com

Registered Office

Narbhavi No. 3, Lakshmanan Street, T Nagar, Chennai, Tamil Nadu, 600017 Telephone: 044-28156653 CIN: L24231TN1990PLC019053 ISIN: INE475E01026 NSE Code: CAPLIPOINT BSE CODE: 524742 Website: www.caplinpoint.net

